Responsiveness to SMO inhibitor treatment in different CLL subgroups
| Responsiveness to SMO inhibitor treatment . | Good, % (n/N) . | Intermediate, % (n/N) . | Resistant, % (n/N) . |
|---|---|---|---|
| Del 13q14 | 37.9 (11/29) | 37.9 (11/29) | 24.1 (7/29) |
| Trisomy 12 | 100 (11/11) | 0 (0/11) | 0 (0/11) |
| Del 17p | 33 (2/6) | 16.6 (1/6) | 50 (3/6) |
| Del 11q | 28.5 (2/7) | 28.5 (2/7) | 42.8 (3/7) |
| Normal karyotype | 31.2 (5/16) | 12.5 (2/16) | 56.2 (9/16) |
| Responsiveness to SMO inhibitor treatment . | Good, % (n/N) . | Intermediate, % (n/N) . | Resistant, % (n/N) . |
|---|---|---|---|
| Del 13q14 | 37.9 (11/29) | 37.9 (11/29) | 24.1 (7/29) |
| Trisomy 12 | 100 (11/11) | 0 (0/11) | 0 (0/11) |
| Del 17p | 33 (2/6) | 16.6 (1/6) | 50 (3/6) |
| Del 11q | 28.5 (2/7) | 28.5 (2/7) | 42.8 (3/7) |
| Normal karyotype | 31.2 (5/16) | 12.5 (2/16) | 56.2 (9/16) |
Response rates to SMO inhibitor treatment in the different genetic subgroups in CLL are shown. Some patients have several chromosomal aberrations and are therefore represented in several subgroups (single patient information, including risk factors and response group, are shown in supplemental Table 2). Cochran-Armitage trend test for trisomy 12 was highly statistically significant (P = .0006; n = 11). No other genetic subgroup showed a statistically significant correlation with any response group.